Corcept Therapeutics Stock News

SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Match Group, Inc., eHealth, Inc., Corcept Therapeutics, Inc., and TransDigm Group Incorporated. If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 708-3993.

It''s been a feast for bears operating on the daily timeframe, as cort has now gone down 4 of the past 5 days. The post Corcept Therapeutics Inc (CORT): Price Down $-0.05 (-0.22)% Over Past Day, Down $-0.05 (-0.22)% Over Past Hour appeared first on ETF Daily News .

Brokerages forecast that Corcept Therapeutics Incorporated (NASDAQ:CORT) will post $101.25 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Corcept Therapeutics earnings, with estimates ranging from $99.60 million to $102.90 million. Corcept Therapeutics posted sales of $85.74 million during the same quarter last year, which []

Nuveen Asset Management LLC cut its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 13.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 382,935 shares of the biotechnology companys stock after selling 57,467 shares during the period. Nuveen Asset Management []

Charles Schwab Investment Management Inc. decreased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 3.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 765,542 shares of the biotechnology companys stock after selling 24,867 shares during the quarter. Charles Schwab Investment Management []

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.

Corcept Therapeutics Incorporated (CORT) CEO Dr. Joseph Belanoff on Q3 2021 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 26.32% and -1.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics is battling to keep drug makers from manufacturing generics of its only commercially available drug while working to create new products. The company is facing a potential lawsuit

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on

New York, New York--(Newsfile Corp. - October 4, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Corcept Therapeutic

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology ( ESMO

MENLO PARK, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe me

MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe me